Acquired resistance to bisphosphonates in Paget's disease of bone

Journal of Bone and Mineral Research

Volumn 22, Issue SUPPL. 2, 2007, Pages

  Papapoulos, Socrates E ^a   Eekhoff, E Marelise W ^a,b   Zwinderman, Aeilko H ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; FARNESYL DIPHOSPHATE; OLPADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; GASTROINTESTINAL SYMPTOM; HUMAN; PAGET BONE DISEASE; REMISSION; SHORT COURSE THERAPY; DRUG RESISTANCE; REVIEW;

DIPHOSPHONATES; DRUG RESISTANCE; HUMANS; OSTEITIS DEFORMANS;

EID: 34247892543     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.06S216     Document Type: Article

References (25)

1. Lyles KW, Siris ES, Singer FR, Meunier PJ 2001 A clinical approach to diagnosis and management of Paget's disease of bone. J Bone Miner Res 16:1379-1387.
2. Papapoulos SE 2002 Pharmacological management of Paget's disease of bone. Clin Rev Bone Miner Metab 1:149-157.
3. Harinck HI, Bijvoet OL, Blanksma HJ, Dahlinghaus-Nienhuys PJ 1987 Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone. Clin Orthop 217:79-98.
4. Schweitzer DH, Zwinderman AH, Vermeij P, Bijvoet OL, Papapoulos SE 1993 Improved treatment of Paget's disease with dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res 8:175-182.
5. Plosker GL, Goa KL 1994 Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 47:945-982.
6. Altman RD 1985 Long-term follow-up of therapy with intermittent etidronate disodium in Paget's disease of bone. Am J Med 79:583-590.
7. Gutteridge DH, Ward LC, Stewart GO, Retallack RW, Will RK, Prince RL, Criddle A, Bhagat CI, Stuckey BG, Price RI, Kent GN, Faulkner DL, Geelhoed E, Gan SK, Vasikaran S 1999 Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another. J Bone Miner Res 14:S2;79-S4.
8. Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ 1999 Effect of multiple intravenous pamidronate courses in Paget's disease of bone. Rev Rhum Engl Ed 66:467-476.
9. Singer FR, Fredericks RS, Minkin C 1980 Salmon Calcitonin Therapy for Paget's disease of bone. The problem of acquired clinical resistance. Arthritis Rheum 23:1148-1154.
10. Lyles KW 2003 What is "resistance" in Paget's disease of bone? Arthritis Rheum 48:2097-2099.
11. Papapoulos SE 1997 Paget's Disease of bone: clinical, pathogenetic and therapeutic aspects. Baillieres Clin Endocrinol Metab 11:117-143.
12. Yates AJ, Percival RC, Gray RE, Atkins RM, Urwin GH, Hamdy NA, Preston CJ, Beneton MN, Russell RG, Kanis JA 1985 Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1:1474-1477.
13. Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL 1987 Paget's disease of bone: Early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD). BMJ 295:1301-1305.
14. Brumsen C, Bloem RM, Papapoulos SE 1882 Paget's disease with osteolytic lesions; combining medical and surgical treatments. Neth J Med 40:292-298.
15. Eekhoff EMW, Zwinderman AH, Haverkort MAD, Papapoulos SE 2003 Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonarte (olpadronate) therapy. Bone 33:831-838.
16. Miller DP, Brown JP, Siris ES, Hoseyni MS, Bekker PJ 1999 A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 106:513-520.
17. Roux C, Gennari C, Farrerons J, Devogelaer JP, Mulder H, Kruse HP, Picot C, Titeux L, Reginster JY, Dougados M 1995 Comparative, prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 38:851-858.
18. Joshua F, Epstein M, Major G 2003 Bisphosphonate resistance in Paget's disease of bone. Arthritis Rheum 48:2321-2323.
19. Cundy T, Wattie D, King AR 1996 High-Dose Pamidronate in the management of resistant Paget's disease. Calcif Tissue Int 58:6-8.
20. Cantrill JA, Anderson DC 1990 Treatment of Paget's disease of bone. Clin Endocrinol (Oxf) 32:507-518.
21. Anderson DC, O'Driscoll JB, Buckler HM, Cantrill J, Brown JD 1988 Relapse of osteoporosis circumscripta as a lytic ring after treatment of Paget's disease with intravenous 3-amino-1-hydroxypropylidene-1,1 bisphosphonate. Br J Radiol 61:996-1001.
22. Reid IR, Miller P, Lyles K, Fraser W, Brown JP, Saidi Y, Mesenbrink P, Su G, Pak J, Zelenakas K, Luchi M, Richardson P, Hosking D 2005 Comparison of a single infusion of zoledronic acid with risedronate in Paget's disease. N Engl J Med 353:898-908.
23. Endo A 1992 The Discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33:1569-1582.
24. Doggrell SA 2001 Statins in the 21st century: End of the simple story? Expert Opin Investig Drugs 10:1755-1766.
25. van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Lowik CWGM, Papapoulos SE 2006 Differentiating the mechanism of antiresorptive action of nitrogen-containing bisphosphonates. Bone 38:167-171.